tarlatamab

Phase Ib shows 61% ORR at 8 mg/kg with manageable safety; data supported selection of 8 mg/kg for the ongoing global phase III EMBOLD SCLC‑301.

Tarlatamab (IMDELLTRA) plus durvalumab showed statistically significant OS, PFS and ORR benefits versus durvalumab alone in Phase 3 DeLLphi‑305 for first‑line maintenance ES‑SCLC.